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Over the past decade there has been substantial increase in
the available antifungal agents for prevention and treatment
of fungal infections. In parallel with this change, transplant
strategies have become more immunosuppressive and less
myelo-suppressive. In light of these two dynamic changes,
true current incidence and outcome of fungal infections in
patients undergoing HCT remain unknown. To address this,
we evaluated incidence and outcome of fungal infections in
patients undergoing HCT in a large pediatric transplant
center with the focus on reduced intensity conditioning (RIC)
transplant, from January 2004-July 2012.
Forty two patients, 30 with non-malignant disease, and 12
with malignant disease were identiﬁed to have proven
fungal infection and reviewed retrospectively. Donor source
was unrelated donor in 35 (83.3%) and matched related in 7
(16.6%). Stem cell source was bone marrow in 31 (73.8%),
peripheral blood stem cells in 7 (16.6%) and cord blood in 4
(9.5%). Thirteen (31%) patients received alemtuzumab and 21
(50%) received antithymocyte globulin (ATG) as part of
conditioning. Fungal infection was deﬁned as a positive
fungal culture in blood or in body ﬂuids or relevant tissue.
In our cohort, highest number of fungal infections was
caused by Candida albicans, followed by Candida glabrata and
Aspergillus species. Table 1 describes the results in detail.
Thirty one (75%) patients had a history of acute (50%) or
chronic GVHD (25%) requiring use of additional immuno-
suppressive therapy. Infection with mold was uncommon in
patients without GVHD. However, there was no difference in
distribution of infection with yeast vs molds in deceased
patients with h/o GVHD. Overall survival for patients with
proven fungal infection was low at 33%. Fungal infection was
attributed to be the cause of death in almost half of the
deceased patients (13/28 patients - 46%).
In our cohort, the overall incidence of culture proven fungal
infection, distribution of different fungal infections, and
patient outcomes are similar to previous reports. Patients
with h/o GVHD and associated immune suppression appear
to be at a higher risk of developing infections with molds
compared to patients without GVHD, where yeast remain
almost an exclusive offender.Table 1
Fungal Infections in pediatric patients undergoing HSCT
Characteristics Number (range/%)
Total number of patients 42
Age in years 11.33 ( 0.52 -28.67)
Proven fungal infections 57
Median post-HSCT day of fungal detection (range) 91.5 (2-2733)
Type of infection
Fungemia only 15
Yeast 12
Mold 3
Invasive infection with organ involvement 27
Yeast 15
Mold 12
Conditioning regimen
MAC 23 (55%)
RIC 18 (43%)
No conditioning 1 (2%)
Patients with GVHD with fungal infection
Total 31/42 (74%)
Acute GVHD 21 (50%)
Chronic GVHD 10 (25%)
Overall outcome
Alive 14 (33%)
Deceased 28 (67%)
Patients deceased due to fungal infection 13/28 (46%)
MAC e Myeloablative conditioning312
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Allogeneic hematopoietic cell transplantation (alloHCT)
recipients are at an increased for Pneumocystis jirovecii
pneumonia (PCP) post-HCT. Current recommendations for
alloHCT recipients includes a prophylactic regimen until at
least six months post alloHCT or longer in patients receiving
immune suppresive therapy (Tomblyn, BBMT 2009). The
Infectious Disease Society of America guidelines recommend
PCP prophylaxis continue in patients with HIV/AIDS until
CD4+ counts are > 200/uL for more than 3 months. To assess
duration of prophylaxis needed, we retrospectively evalu-
ated 100 patients who received alloHCT for myeloid malig-
nances between 2006 and 2011. Incidence of PCP infection
and toxicity to prophylactic regimen were also evaluated.
Characteristics of the 100 patients are shown (Table 1). 66
patients received systemic steroids post-transplant and 26
patients received anti-thymocyte globulin (ATG) during
conditioning. Primary PCP prophylaxis consisted of trimeth-
oprim-sulfamethoxazole (TMP/SMX) (91%) or pentamadine
(9%). Toxicity to ﬁrst-line therapy did not occur in 61% of
patients and for 7% of patients' toxicity status was unknown.
Toxicity from TMP/SMXoccurred in 32% of patients including
hematologic (78%), dermatologic 6.3%, renal 3.1%, gastroin-
testinal 3.1%, and drug interaction 3.1%. At last contact 36% of
patients had PCP prophylaxis discontinued with CD4+ count
evaluated in 26 patients. At discontinuation in these patients,
the mean CD4+ count was 411/ uL and only 5 patients had
a CD4+ count < 200/uL. Median duration of PCP prophylaxis
was 327 (26-2175) days in all patients evaluated, 369 (38-
2175) days if alive at date of last contact (DLC) (n¼55), 408
(141-2150) days in patients who completed prophylaxis and
were alive at DLC, and 425 (127-2175) days if alive at DLC after
receiving ATG (n¼15). Median time to TMP/SMX toxicity was
Table 1
Variables N ¼ 100
Age at transplant, years, median (range) 51.8 (22-74)
Gender
Male 51
Female 49
Primary Diagnosis
AML 61
CML 5
MDS 29
MPS 4
MYF 1
Received Systemic steroids
Yes 66
No 34
Received ATG
Yes 26
No 74
Conditioning Intensity
Myeloablative 92
Reduced intensity/non-myeloablative 8
Donor Type
Matched related 33
Matched unrelated 38
Mismatched related 2
Mismatched unrelated 25
Umbilical cord blood 2
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therapy at DLC. 20.3% of these patients had stopped PCP
prophylaxis. One patient had PCP requiring hospital admis-
sion 146 days after HCT. This patient received myeloablative
conditioning with ATG followed by mismatched unrelated
donorHCT. At timeof PCP infection, patientwas on tacrolimus
and 40mg of prednisone for GVHD treatment and was
receiving pentamidine for PCP prophylaxis.
In summary, the incidence of PCP is rare in the post alloHCT
population. Our data suggests PCP prophylaxis can be safely
discontinued if CD4+ counts > 200/uL and if not on systemic
steroids.Pre-restrictive Approach Restrictive Approach
Day 100 Mortality 2/100 3/100
1-year Mortality 11/100 8/100313
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Background: Tacrolimus has been widely used for the
prophylaxis or treatment of graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation
(HSCT). Among its side effects, nephrotoxicity is often clini-
cally problematic. Recipients of HSCTare highly susceptible to
the infectiondue todrug-resistant grampositivebacteria, and
thus nephrotoxic glycopeptide antimicrobial agents such as
teicoplanin and vancomycin are often administered. Since the
nephrotoxicity of coadministration of teicoplanin and tacro-
limus has yet to be evaluated, it was retrospectively evaluated
in the setting of allogeneic HSCT.
Patients & Methods: Recipients of allogeneic HSCT for
hematological diseases who received intravenous teicopla-
nin for more than 4 days during the continuous intravenous
infusion of tacrolimus within 30 days after transplantation
were selected from the data base. Patients who received
liposomal amphotericin-B or foscarnet were excluded. The
data including patient demographics, whole blood concen-
tration of tacrolimus, dose and duration of teicoplanin
administration, and serum creatinine (sCr) were collected.
Therapeutic drug monitoring of tacrolimus and teicoplanin
was performed in all the patients.
Results: Sixty-seven patients fulﬁlled criteria, and were
included in the analysis. Median age of the patients was 48
years (range: 16-62), and median duration of the coadmin-
istration of teicoplanin and tacrolimus was 11 days (range: 4-
40). Mean whole blood concentration of tacrolimus during
teicoplanin administration were 16.3+1.7 ng/ml. Twice or
greater increases of sCr compared with that before initiating
teicoplanin were observed only in 2 (3.0%) of 67 patients.
Nephrotoxicity was reversible andmanageable in all cases by
discontinuation of teicoplanin with or without dose adjust-
ment of tacrolimus.
Conclusion: Teicoplanin can safely be coadministered with
tacrolimus even in the early post-transplant period under
the appropriate management with therapeutic drug moni-
toring of each drug.314
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Introduction: The beneﬁts of a restrictive transfusion
approach (i.e. improved survival/ decreased infections) have
been demonstrated in a variety of hospitalized patient pop-
ulations. There are little data in the oncology setting outside
of the transplantation programs successfully treating
Jehovah Witnesses, who generally decline blood product
support. The University of Alabama at Birmingham adopted
a hospital wide restrictive transfusion policy in February,
2008; speciﬁcally in non-bleeding patients, the threshold for
transfusion is 7 g/dl and 1 unit of red cells is to be transfused
and the patient reassessed prior to considering additional
transfusions. Our stem cell transplant program adopted this
policy with the exception that patients with diastolic/systolic
dysfunction were maintained at a higher hemoglobin.
Objective: The purpose of this outcome analysis is to review
the impact of a restrictive red cell transfusion approach in
multiple myeloma patients undergoing autologous PBSC
transplant.
Materials and methods: We collected data for 200 multiple
myeloma subjects: 100 patients transplanted in 2005-2007
were compared to 100 patients who underwent trans-
plantation utilizing the restrictive transfusion policy (2009-
2011). Initial analysis included Day 100 and 1- year mortality
recognizing that the latter could be inﬂuenced bymany other
factors, including disease recurrence.
Results/Conclusion: Day 100 and 1- year mortality were not
adversely affected by the adoption of a restrictive transfusion
approach. A statistical difference was not expected as the
mortality associated with auto PBSC for multiple myeloma is
low. Further analysis of our entire multiple myeloma pop-
ulation will be presented. Analysis will include the impact of
a restrictive transfusion approach on transplant-related co-
morbidities, particularly infections. Additionally, we will
compare the number of blood products utilized in these 2
cohorts.315
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Background: HFS, an adverse reaction associated with
certain chemotherapeutic agents, is characterized by dyses-
thesias in hands and feet. No cases of HFS with total body
